Estrace

PreclinicalSmall molecule

UUniversity of Virginia

Estrace is one of 7 small molecule programs targeting Progesterone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProgesteroneTerminated

ProgesteronePreclinical

Terminated

Competition

Competitive Landscape

7 competitors in Progesterone

#DrugCompanyPhaseTrials

Prometrium

Ferring

Approved

49 2

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

14 3

Activella

Eli Lilly

Preclinical

1 4

Ulipristal Acetate

AbbVie

Preclinical

1 5

Prometrium

SSolvay Pharmaceuticals

Preclinical

1 6

Estrace

UUniversity of Virginia

Preclinical

4 7

Dydrogesterone Pill

NNational University of Malaysia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Progesterone4 trials

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Completed·UUniversity of Virginia·N/A·NCT01427595·25 enrolled

Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

Terminated·UUniversity of Virginia·N/A·NCT01428245·3 enrolled

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Terminated·UUniversity of Virginia·N/A·NCT01428193·4 enrolled

Show 1 more trial

Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

Unknown status·UUniversity of Virginia·N/A·NCT01425541·60 enrolled

Atrophy2 trials

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

Completed·PPrasco LLC·Phase 3·NCT03332303·540 enrolled

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

Completed·PPadagis LLC·Phase 3·NCT02770365·695 enrolled

Breast Cancer1 trial

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Terminated·GGeorgetown University·Phase 2·NCT00661531·11 enrolled

Menopause1 trial

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

Completed·NNYU Langone Health·N/A·NCT04544475·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Estrace. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Estrace compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Estrace. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Virginia

Estrace

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Progesterone4 trials

Atrophy2 trials

Breast Cancer1 trial

Menopause1 trial

References

Drug Info

Quick Facts

Related News